Patients' characteristics
| . | BMT: no. (%), [range] . | CBT: no. (%), [range] . | Total (%) . | P . |
|---|---|---|---|---|
| Recipient sex, male/female | 35 (32)/24 (22) | 26 (24)/23 (21) | NS | |
| Recipient age, y | 49.2 (mean) [20-66] | 47.3 (mean) [19-67] | NS | |
| Donor sex, male/female | 37 (34)/22 (20) | 24 (22)/25 (23) | NS | |
| Donor age, y | 36.7 (mean) [17-66] | 0 | < .001 | |
| No. of infused cell, /kg | 2.80 × 108 (mean) [0.92-4.02] | 0.28 × 108 (mean) [0.18-0.50] | < .001 | |
| Primary disease | NS | |||
| AML/advanced MDS | ||||
| CR | 14 (13) | 11 (10) | 25 (23) | |
| non-CR | 21 (19) | 14 (13) | 35 (32) | NS |
| Total | 35 (32) | 25 (23) | 60 (56) | |
| ALL | ||||
| CR | 3 (3) | 3 (3) | 6 (6) | |
| non-CR | 2 (2) | 10 (9) | 12 (11) | NS |
| Total | 5 (5) | 13 (12) | 18 (17) | |
| Lymphoma | ||||
| CR | 7 (6) | 3 (3) | 10 (9) | |
| non-CR | 12 (11) | 8 (7) | 20 (19) | NS |
| Total | 19 (18) | 11 (10) | 30 (28) | |
| Conditioning regimen | < .01 | |||
| TBI/CY | 28 (26) | 24 (22) | ||
| BU/CY | 14 (13) | 0 (0) | ||
| RIC | 17 (16) | 25 (23) | ||
| GVHD prophylaxis | < .001 | |||
| TAC + sMTX | 51 (47) | 6 (6) | ||
| CSP + sMTX | 8 (7) | 28 (26) | ||
| CSP + MMF | 0 (0) | 15 (14) | ||
| HLA disparity | < .001 | |||
| 6/6 | 39 (36) | 1 (1) | ||
| 5/6 | 20 (19) | 7 (6) | ||
| 4/6 | 0 (0) | 22 (20) | ||
| 3/6 | 0 (0) | 19 (18) | ||
| Days required for engraftment | 25 (median) [15-32] | 32 (median) [14-39] | < .01 |
| . | BMT: no. (%), [range] . | CBT: no. (%), [range] . | Total (%) . | P . |
|---|---|---|---|---|
| Recipient sex, male/female | 35 (32)/24 (22) | 26 (24)/23 (21) | NS | |
| Recipient age, y | 49.2 (mean) [20-66] | 47.3 (mean) [19-67] | NS | |
| Donor sex, male/female | 37 (34)/22 (20) | 24 (22)/25 (23) | NS | |
| Donor age, y | 36.7 (mean) [17-66] | 0 | < .001 | |
| No. of infused cell, /kg | 2.80 × 108 (mean) [0.92-4.02] | 0.28 × 108 (mean) [0.18-0.50] | < .001 | |
| Primary disease | NS | |||
| AML/advanced MDS | ||||
| CR | 14 (13) | 11 (10) | 25 (23) | |
| non-CR | 21 (19) | 14 (13) | 35 (32) | NS |
| Total | 35 (32) | 25 (23) | 60 (56) | |
| ALL | ||||
| CR | 3 (3) | 3 (3) | 6 (6) | |
| non-CR | 2 (2) | 10 (9) | 12 (11) | NS |
| Total | 5 (5) | 13 (12) | 18 (17) | |
| Lymphoma | ||||
| CR | 7 (6) | 3 (3) | 10 (9) | |
| non-CR | 12 (11) | 8 (7) | 20 (19) | NS |
| Total | 19 (18) | 11 (10) | 30 (28) | |
| Conditioning regimen | < .01 | |||
| TBI/CY | 28 (26) | 24 (22) | ||
| BU/CY | 14 (13) | 0 (0) | ||
| RIC | 17 (16) | 25 (23) | ||
| GVHD prophylaxis | < .001 | |||
| TAC + sMTX | 51 (47) | 6 (6) | ||
| CSP + sMTX | 8 (7) | 28 (26) | ||
| CSP + MMF | 0 (0) | 15 (14) | ||
| HLA disparity | < .001 | |||
| 6/6 | 39 (36) | 1 (1) | ||
| 5/6 | 20 (19) | 7 (6) | ||
| 4/6 | 0 (0) | 22 (20) | ||
| 3/6 | 0 (0) | 19 (18) | ||
| Days required for engraftment | 25 (median) [15-32] | 32 (median) [14-39] | < .01 |
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BMT, bone marrow transplantation; BU, busulfan; CBT, cord blood transplantation; CR, complete remission; CSP, cyclosporine; CY, cyclophosphamide; GVHD, graft- versus-host disease; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; NS, not significant; RIC, reduced-intensity conditioning; sMTX, short-term methotrexate; TAC, tacrolimus; and TBI, total body irradiation.